Literature DB >> 20381295

Weaning difficult-to-wean chronic obstructive pulmonary disease patients: a pilot study comparing initial hemodynamic effects of levosimendan and dobutamine.

Lamia Ouanes-Besbes1, Islem Ouanes, Fahmi Dachraoui, Saoussen Dimassi, Alexandre Mebazaa, Fekri Abroug.   

Abstract

PURPOSE: To compare the short-term hemodynamic effects of levosimendan and dobutamine in chronic obstructive pulmonary disease (COPD) patients experiencing weaning difficulties in relation with increased left ventricular filling pressure.
MATERIALS AND METHODS: This prospective, sequential, pilot study included 10 COPD patients experiencing weaning difficulties in relation with increased left ventricular filling pressure ascertained by an increase >10 mm Hg of pulmonary artery occlusion pressure (PAOP) at the shift from mechanical to spontaneous breathing (SB). Patients received 1 h infusion of 7 μg/kg per minute of dobutamine, followed by 24-hour infusion of 0.2 μg/kg per minute levosimendan. Hemodynamic variables were measured under MV and 15 to 30 minutes after SB at baseline, at the end of dobutamine infusion, at a washout period, and after levosimendan infusion.
RESULTS: At baseline, the shift from mechanical ventilation to spontaneous ventilation was associated with a significant increase in PAOP from a median of 15 (interquartile range [IQR], 6) to 29 (9) mm Hg. Both drugs reduced significantly the level of PAOP increase at SB, but levosimendan had a greater effect than dobutamine [median PAOP increase (IQR): 5 (2) vs 9 (4) mm Hg, respectively; P < .01].
CONCLUSIONS: Both drugs reduced the magnitude of PAOP increase at SB in difficult-to-wean COPD patients. PAOP increase was reduced to a greater extent by levosimendan.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20381295     DOI: 10.1016/j.jcrc.2010.01.002

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  12 in total

Review 1.  Weaning-induced cardiac dysfunction: where are we today?

Authors:  Jean-Louis Teboul
Journal:  Intensive Care Med       Date:  2014-05-27       Impact factor: 17.440

2.  Levosimendan is superior to dobutamine as an inodilator in the treatment of pulmonary hypertension for children undergoing cardiac surgery.

Authors:  Abdelhay A Ebade; Mohamed A Khalil; Ahmed K Mohamed
Journal:  J Anesth       Date:  2012-12-09       Impact factor: 2.078

3.  Use of levosimendan in critically ill patients with severe aortic stenosis and left ventricular dysfunction.

Authors:  Francisca Caetano; Paula Mota; Sérgio Barra; Inês Almeida; Ana Botelho; Joana Trigo; António L Marques
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2012-12

Review 4.  Year in review 2010: Critical Care--Cardiology.

Authors:  Daniel De Backer; Sabino Scolletta
Journal:  Crit Care       Date:  2011-12-05       Impact factor: 9.097

Review 5.  Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.

Authors:  Zoltán Papp; Piergiuseppe Agostoni; Julian Alvarez; Dominique Bettex; Stefan Bouchez; Dulce Brito; Vladimir Černý; Josep Comin-Colet; Marisa G Crespo-Leiro; Juan F Delgado; István Édes; Alexander A Eremenko; Dimitrios Farmakis; Francesco Fedele; Cândida Fonseca; Sonja Fruhwald; Massimo Girardis; Fabio Guarracino; Veli-Pekka Harjola; Matthias Heringlake; Antoine Herpain; Leo M A Heunks; Tryggve Husebye; Višnja Ivancan; Kristjan Karason; Sundeep Kaul; Matti Kivikko; Janek Kubica; Josep Masip; Simon Matskeplishvili; Alexandre Mebazaa; Markku S Nieminen; Fabrizio Oliva; Julius G Papp; John Parissis; Alexander Parkhomenko; Pentti Põder; Gerhard Pölzl; Alexander Reinecke; Sven-Erik Ricksten; Hynek Riha; Alain Rudiger; Toni Sarapohja; Robert H G Schwinger; Wolfgang Toller; Luigi Tritapepe; Carsten Tschöpe; Gerhard Wikström; Dirk von Lewinski; Bojan Vrtovec; Piero Pollesello
Journal:  J Cardiovasc Pharmacol       Date:  2020-07       Impact factor: 3.105

Review 6.  Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use.

Authors:  Zoltán Papp; Piergiuseppe Agostoni; Julian Alvarez; Dominique Bettex; Stefan Bouchez; Dulce Brito; Vladimir Černý; Josep Comin-Colet; Marisa G Crespo-Leiro; Juan F Delgado; Istvan Édes; Alexander A Eremenko; Dimitrios Farmakis; Francesco Fedele; Cândida Fonseca; Sonja Fruhwald; Massimo Girardis; Fabio Guarracino; Veli-Pekka Harjola; Matthias Heringlake; Antoine Herpain; Leo Ma Heunks; Tryggve Husebye; Višnja Ivancan; Kristjan Karason; Sundeep Kaul; Matti Kivikko; Janek Kubica; Josep Masip; Simon Matskeplishvili; Alexandre Mebazaa; Markku S Nieminen; Fabrizio Oliva; Julius-Gyula Papp; John Parissis; Alexander Parkhomenko; Pentti Põder; Gerhard Pölzl; Alexander Reinecke; Sven-Erik Ricksten; Hynek Riha; Alain Rudiger; Toni Sarapohja; Robert Hg Schwinger; Wolfgang Toller; Luigi Tritapepe; Carsten Tschöpe; Gerhard Wikström; Dirk von Lewinski; Bojan Vrtovec; Piero Pollesello
Journal:  Card Fail Rev       Date:  2020-07-08

7.  Left ventricular-arterial coupling is associated with prolonged mechanical ventilation in severe post-cardiac surgery patients: an observational study.

Authors:  Xu Wang; Yun Long; Huaiwu He; Guangliang Shan; Rui Zhang; Na Cui; Hao Wang; Xiang Zhou; Xi Rui; Wanglin Liu
Journal:  BMC Anesthesiol       Date:  2018-12-06       Impact factor: 2.217

8.  Contribution of Levosimendan in Weaning from Mechanical Ventilation in Patients with Left Ventricular Dysfunction: A Pilot Study.

Authors:  Ifigeneia Kaltsi; Epameinondas Angelopoulos; Georgios Tzanis; Antonios Sideris; Konstantinos Tyrovolas; Stelios Kokkoris; Christina Gratziou; Serafeim Nanas; Christina Routsi
Journal:  Crit Care Res Pract       Date:  2019-07-24

Review 9.  Levosimendan: current data, clinical use and future development.

Authors:  M S Nieminen; S Fruhwald; L M A Heunks; P K Suominen; A C Gordon; M Kivikko; P Pollesello
Journal:  Heart Lung Vessel       Date:  2013

Review 10.  Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper.

Authors:  Antoine Herpain; Stefaan Bouchez; Massimo Girardis; Fabio Guarracino; Johann Knotzer; Bruno Levy; Tobias Liebregts; Piero Pollesello; Sven-Erik Ricksten; Hynek Riha; Alain Rudiger; Fabio Sangalli
Journal:  J Cardiovasc Pharmacol       Date:  2019-01       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.